Touchlight shortlisted for London Award for Innovation

We are delighted to announce that Touchlight has been shortlisted for the London Award for Innovation in the 25th Anniversary London First Awards. See full article here.

London First are a non-profit organisation with the mission to make London the best city in the world to do business. They aim to influence national and local government policies and investment decisions to support London’s global competitiveness.

London First hosts an annual awards black tie dinner to reward and mark key individuals, activities, companies and projects that have contributed to making London the best city in the world in which to work, study and play.

The award winner will be chosen from the shortlist of three based on a public vote, and the winner will be announced at the awards dinner on the 25th of January. Support Touchlight’s nomination by voting here. Voting closes 9th December.

- ENDS -

About Touchlight

Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.

For more information please contact: